CAPLYTA Shows Superior Efficacy Among Adjunctive Depression Treatments in First Network Meta-Analysis
核心洞察
CAPLYTA (lumateperone) ranked highest among FDA-approved adjunctive therapies for major depressive disorder (搜索) across four efficacy measures in a network meta-analysis of 10 randomized clinical trials.
The analysis demonstrated CAPLYTA's superior performance in reducing depression symptoms, with no statistically significant weight gain compared to placebo plus antidepressant therapy.
The study provides indirect comparative evidence to help inform treatment decisions for adults with MDD (搜索) who do not achieve adequate symptom control with antidepressants alone.
Johnson & Johnson announced findings from the first network meta-analysis comparing CAPLYTA (lumateperone) to FDA-approved atypical antipsychotics for adjunctive treatment of major depressive disorder (搜索) in adults. The analysis, drawing on data from 10 registrational randomized clinical trials, found that CAPLYTA was favored across four efficacy measures based on indirect comparisons from placebo plus antidepressant therapy-controlled trials.
The findings were presented at the 2026 Neuroscience Education Institute (搜索) Spring Congress in Kissimmee, Florida, providing clinicians with comparative insights in a therapeutic area where head-to-head trials are limited.
Superior Efficacy Across Multiple Measures
The network meta-analysis evaluated five atypical antipsychotics approved by the FDA as adjunctive therapy for adults with MDD (搜索): aripiprazole (Abilify), brexpiprazole (Rexulti), cariprazine (Vraylar), lumateperone (CAPLYTA), and quetiapine XR (Seroquel XR).
CAPLYTA demonstrated the largest effect size among all five treatments evaluated across four efficacy outcomes:
- MADRS change from baseline: Mean difference -4.71 (95% credible intervals -5.78, -3.63)
- MADRS response: Odds ratio 2.33 (95% CrI 1.77, 3.05)
- MADRS remission: Odds ratio 2.22 (95% CrI 1.57, 3.07)
- CGI-S change from baseline: Mean difference -0.60 (95% CrI -0.74, -0.46)
"The goal of treating patients with MDD (搜索) should be remission of symptoms, which may mean adding to their current treatment in order to achieve the best outcomes," said Andrew J. Cutler, M.D., lead author of the analysis and Chief Medical Officer at the Neuroscience Education Institute (搜索). "This analysis is valuable because it gives us indirect comparative insights in a space where we don't have head-to-head trials, which may inform treatment discussions in everyday clinical practice."
Favorable Safety Profile
The analysis also evaluated safety outcomes, with CAPLYTA demonstrating notable advantages in weight-related measures. CAPLYTA showed no statistically significant weight gain compared to placebo plus antidepressant therapy, ranking most favorably among all treatments on both weight-related outcomes:
- Mean weight change from baseline: -0.08 (95% CrI -0.30, 0.13; 77% probability of superiority)
- Clinically meaningful weight increase ≥7%: Odds ratio 0.41 (95% CrI 0.04, 1.42; 94% probability of lower risk)
CAPLYTA had a 100% probability of superiority versus all comparators on mean weight change. Additionally, CAPLYTA was the only treatment comparable to placebo plus antidepressant therapy for the risk of akathisia, with the remaining four treatments showing higher akathisia risk.
Addressing Unmet Medical Need
Major depressive disorder (搜索) affects an estimated 332 million people worldwide, representing about 4% of the global population. In the United States alone, approximately 22 million adults live with the disease. Despite available treatments, only one in three patients reach remission with their first antidepressant, with rates continuing to decline with each subsequent treatment attempt.
"The adjunctive treatments approved for MDD (搜索) share a common indication but differ in their pharmacologic profiles, efficacy, and tolerability," said Leonardo Diaz, M.D., Vice President of U.S. Medical Affairs for CAPLYTA at Johnson & Johnson. "This NMA provides indirect comparative evidence derived from placebo-controlled studies that may help inform treatment decisions, reinforcing the role of CAPLYTA as an important treatment option for the many adults with MDD who do not achieve adequate symptom control with an antidepressant alone."
Study Methodology
The network meta-analysis used a Bayesian statistical framework with a star-shaped network design, with antidepressant therapy plus placebo as the common comparator. The analysis included 10 randomized, double-blind, parallel-group, placebo-controlled trials identified through systematic literature review using clinical studies data from each product's U.S. prescribing information.
To reflect clinical decision-making, doses were pooled within treatments, resulting in five treatment nodes. The study evaluated four efficacy outcomes and four safety outcomes, though additional safety measures were not assessed due to inconsistent reporting across trials.
Clinical Implications
Network meta-analysis represents a structured, protocol-driven analytical process widely accepted by regulatory agencies, health technology assessment agencies, and medical guideline committees for comparing treatment options when direct head-to-head trials are unavailable. However, as these analyses rely on indirect comparisons across studies that may differ in design and patient populations, findings should be interpreted alongside the totality of evidence.
CAPLYTA is currently approved as an oral, once-daily atypical antipsychotic for adults as adjunctive therapy with antidepressants for major depressive disorder (搜索), schizophrenia (搜索), and depressive episodes associated with bipolar I or II disorder. The medication's efficacy may be mediated through a combination of antagonist activity at central serotonin 5-HT2A receptors (搜索) and partial agonist activity at central dopamine D2 receptors (搜索).